Barrett’s oesophagus: Current controversies

doi:10.3748/wjg.v23.i28.5051

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16645)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

1359

WORD

322

HTML

10044

Figures (1-2)

321

Tables (1-4)

295

Sum=12341

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

570

Download

884

Sum=1454

Publishing Process of This Article

Item

Count

Browse

1167

Download

1683

Sum=2850

Jul 28, 2017 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 28, 2017; 23(28): 5051-5067
Published online Jul 28, 2017. doi: 10.3748/wjg.v23.i28.5051

Table 4 Summary of molecular biomarkers predicting malignant progression

Biomarker	Phase	Sample size	End-point
Biomarker panels
8-gene methylation panel	3	195	High grade dysplasia/adenocarcinoma
DNA content abnormalities and loss of heterozygosity	4	243	Adenocarcinoma
Expert low grade dysplasia, aneuploidy, Aspergillus oryzae lectin	3	380	Adenocarcinoma
DNA content abnormalities
Aneupolidy/tetraploidy	4	322	Adenocarcinoma
Tumour suppressor loci
p53 loss of heterozygosity	4	256	Adenocarcinoma
p53 staining	4	48	High grade dysplasia/adenocarcinoma
Epigenetics
P16 methylation	3	53	HD/adenocarcinoma
Proliferation
Mcm2	3	27	Adenocarcinoma
Clonal diversity
Clonal diversity measures	4	239	Adenocarcinoma
Cell cycle markers
Cyclin A	3	48	High grade dysplasia/adenocarcinoma
Cyclin D1	3	307	Adenocarcinoma
Serum biomarkers
Leukocyte telomere length	4	300	Adenocarcinoma
Selenoprotein P	4	361	Adenocarcinoma

Citation: Amadi C, Gatenby P. Barrett’s oesophagus: Current controversies. World J Gastroenterol 2017; 23(28): 5051-5067
URL: https://www.wjgnet.com/1007-9327/full/v23/i28/5051.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i28.5051